PRESCRIBERS |
|
|
Main prescribers: General practitioners |
76.65% |
|
RATE OF USE |
|
Annual consumption (DDD) |
26,564,572 |
|
Standardised rate of use (per 100,000 insured persons) |
231,697.90 |
|
Average annual consumption per patient (DDD) |
139.67 |
|
% Insured persons concerned |
1.66% |
|
Approximate % DDD issued outside the insurance |
10.75% |
|
% Patients with more than 3 times the average consumption |
7.05% |
|
POPULATION |
|
|
Median age |
62 years |
|
Max/min ratio of the median age (by district) |
1.16 |
Percentage of women |
53.28% |
Ratio Preferential scheme/General scheme |
3.39 |
|
CONSUMPTION TRENDS (DDD) |
|
|
Trend 2011-2021 |
10.06% |
|
Trend 2011-2019 |
11.15% |
|
Trend 2019-2021 |
5.80% |
GEOGRAPHICAL VARIATIONS |
|
|
Coefficient of variation 2011-2013 |
20.68 |
|
Coefficient of variation 2019-2021 |
17.88 |
Max/min ratio of consumption (DDD per 100,000 insured persons, by region) |
1.40 |
|
Max/min ratio of consumption ( DDD per 100,000 insured persons, by district) |
2.14 |
DIRECT EXPENDITURE |
|
|
Annual expenditure charged to the insurance |
16,835,484€ |
|
Average annual expenditure per insured person |
1.47 € |
|
Average patient share (under insurance) |
18.95% |
|
Max/min ratio of expenditure per insured person (by region) |
1.41 |
|
Max/min ratio of expenditure per insured person (by disctrict) |
1.94 |
|
% “Low-cost” medication |
99.61% |
|
On this table, when a statistical test has been performed, the data showing a significant difference is displayed on an yellow background, otherwise on a grey background.
CODES |
LABEL |
LABEL ATC-5 |
N03AX12 |
GABAPENTINE |
AUTRES ANTIEPILEPTIQUES |
N03AX16 |
PREGABALINE |
AUTRES ANTIEPILEPTIQUES |
The labels on a blue background are the medicines that exist under the status "low cost".
The codes mentioned above can be used in rates and expenses, or only in expenses. We invite you to consult the full report for more information.
Click here to see the graph illustrating the evolution of the breakdown by volume of ATC codes used for the rates.
WE ARE INTERESTED IN YOUR OPINION
Do you have any experience in this area ? We listen to you !
Send us an email